宁科生物(600165) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company projects a net loss for the first half of 2025, with attributable net profit between -200 million CNY and -160 million CNY, and non-recurring net profit between -150 million CNY and -110 million CNY Performance Forecast Details | Indicator | Estimated Amount (CNY) | | :--- | :--- | | Performance Forecast Period | January 1, 2025 to June 30, 2025 | | Net Profit Attributable to Shareholders of the Listed Company | -200 million CNY to -160 million CNY | | Net Profit After Deducting Non-Recurring Gains and Losses | -150 million CNY to -110 million CNY | - This performance forecast represents the company's finance department's preliminary estimation and has not been audited by a certified public accountant[3] Prior Period Performance Review Compared to the prior year, the company's projected loss for the first half of 2025 has narrowed, with the 2024 corresponding period showing an attributable net loss of 424.9641 million CNY and a non-recurring net loss of 412.9578 million CNY Prior Period Performance (H1 2024) | Indicator (H1 2024) | Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Shareholders of the Listed Company | -424.9641 million CNY | | Net Profit After Deducting Non-Recurring Gains and Losses | -412.9578 million CNY | | Earnings Per Share | -0.620 CNY | - Compared to the prior period, the projected attributable net loss for the current period (between -200 million CNY and -160 million CNY) shows a significant narrowing from -424.9641 million CNY in the prior corresponding period[2][4] Analysis of Current Period Pre-Loss The current period's loss is primarily due to insufficient capacity utilization at Ningxia Zhongke Biomaterials Co., Ltd., leading to unabsorbed fixed costs, and the accrual of expenses related to investor misrepresentation lawsuits - Core operational issue: The subsidiary, Ningxia Zhongke Biomaterials Co., Ltd., experienced insufficient capacity utilization, preventing the effective absorption of fixed costs such as depreciation of fixed assets and public utility operating expenses, contributing to the loss[6] - Non-operating expense: Accrual of litigation expenses related to investor misrepresentation lawsuits further increased the loss for the current period[6] Risk Warning The company emphasizes that this performance forecast is an unaudited preliminary calculation with inherent uncertainties, and no other significant factors affecting its accuracy have been identified as of the announcement date - This performance forecast is a preliminary calculation by the company's finance department based on its professional judgment, is unaudited by a certified public accountant, and the final results may differ[7] - As of the announcement date, the company has not identified any other significant uncertain factors that could affect the accuracy of this performance forecast[7] Other Explanations The company reiterates that the data in this announcement are preliminary, and the final accurate financial figures will be based on the officially disclosed 2025 semi-annual report, urging investors to be aware of investment risks - The final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to pay attention to investment risks[8]